[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 649
Citations 0
Research Letter
September 2016

Trends in Stimulant Medication Use in Commercially Insured Youths and Adults, 2010-2014

Author Affiliations
  • 1Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore
  • 2Department of Psychiatry, University of Maryland, Baltimore
  • 3Center for Collaborative Studies, Health Care Service Corporation, Enterprise Clinical Analytics, Blue Cross and Blue Shield, Richardson, Texas
  • 4Health Care Service Corporation, Enterprise Clinical Analytics, Enterprise Network Solutions, Blue Cross and Blue Shield, Chicago, Illinois
  • 5Department of Psychiatry, Johns Hopkins Medical Institutions, Baltimore, Maryland
  • 6Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland
JAMA Psychiatry. 2016;73(9):992-993. doi:10.1001/jamapsychiatry.2016.1182

Stimulants are the most commonly prescribed treatment of attention-deficit/hyperactivity disorder (ADHD) in youths, and according to a nationally representative US household survey, there has been a sizeable increase in stimulant use among youth, from 4.0% between 1996 and 1998 to 6.6% between 2010 and 2012.1 Also, during the last decade, the US Food and Drug Administration approved an indication for stimulant use in adults to treat ADHD.

First Page Preview View Large
First page PDF preview
First page PDF preview
×